Zosano Pharma Corporation ZSANQ OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score

27/100

1/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Zosano Pharma Corporation (ZSANQ) generated $-8.54M in operating cash flow for quarter ending 2022-03-31. After capital expenditures of $65K, free cash flow was $-8.61M.

Free cash flow margin was -6518.9% of revenue. Cash conversion ratio was 0.26x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
MOAT (0/100, Fail) — limited free cash flow weakens the competitive position
INCOME (10/100) — Cash conversion ratio was 0.26x suggests some earnings are non-cash items

Overall SharesGrow Score: 25/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

27/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

HEALTH

50/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

0/100

Proven by this page

✓

GROWTH

73/100

→ Income

✗

INCOME

10/100

→ Income

Zosano Pharma Corporation Cash Flow History

Metric	TTM	Q1 FY2022	Q4 FY2021	Q3 FY2021	Q2 FY2021
Operating Cash Flow	$-28.67M	$-8.54M	$-5.83M	$-6.32M	$-7.98M
Capital Expenditure	$-2.25M	$-65K	$-408K	$-592K	$-1.19M
Free Cash Flow	$-30.92M	$-8.61M	$-6.24M	$-6.91M	$-9.17M